Harmony Biosciences Holdings, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $868.5M | $714.7M | $582.0M | $437.9M | $305.4M |
| Gross profit | $670.1M | $557.9M | $460.8M | $354.4M | $249.9M |
| Operating income | $208.5M | $190.8M | $192.0M | $120.2M | $87.5M |
| Operating expenses | $461.6M | $367.1M | $268.8M | $234.2M | $162.4M |
| Cost of revenue | $198.3M | $156.8M | $121.2M | $83.5M | $55.5M |
| Cash from operations | $348.2M | $219.8M | $219.4M | $144.5M | $98.6M |
| Capital expenditure | $310,000 | $1.2M | $312,000 | $172,000 | $298,000 |
| Free cash flow | $347.9M | $218.7M | $219.1M | $144.3M | $98.3M |
| Share repurchases | — | — | $100.0M | — | — |
| Total assets | $1.3B | $999.2M | $811.4M | $673.9M | $433.4M |
| Total liabilities | $401.4M | $340.0M | $344.5M | $271.0M | $246.9M |
| Total debt | $165.0M | $181.2M | $196.2M | $197.5M | $199.5M |
Shares outstanding 57.9M · Free float 60.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.